COMPASSION RESPONSE NETWORK

Main Index --- Treatments Index --- Circulars Index

COMPASSION RESPONSE NETWORK CIRCULAR No 23

It is one of the primary objectives of Compassion Response Network, to provide comparative trials of alternative treatments for three HIV/AIDS patients each taking the treatment over six months. Pre-treatment, as well as at intervals during the treatment, we take blood samples of each of the patients to test for HIV viral load (bDNA test) and the strength of the immunity system (CD4 count). Every few monmths, the patient has a comprehensive medical examination. The results are then openly published on our CRN website, so to provide an independent survey of the effectiveness of the treatment with respect to the patients we treated.

CRN is a public charitable organisation funding its projects from public donations. Because of the limited flow of donations, we are able only to test one alternative treatment at a time. During 2004/2005 we trialled Imusil on two HIV/AIDS patients with fair results which can be seen on our website.

During 2005, we commenced a trial on three HIV/AIDS patients commencing 22/September/05, over six months using pure colloidal silver + oxyrich.

Compassion Response Network supplied 2 ½ litres of pure colloidal silver + 1 litre of Oxyrich, purchased from Australian distributor Karen Taranto of Vital Breath ph (613) 5237 7997, postal Karen Taranto 8 McLenon St, Appollo Bay 3233, Australia. Karen in turn received the products from Australian Natural Colloids.

This was sufficient product to supply three patients each with treatment over 6 months each, each receiving 5 mls pure colloidal silver, and 2 mls Oxyrich daily.

The colloidal silver is given early in the morning before eating or drinking so the mouth will be dry and will adsorb the colloid very well. If early in the morning is too difficult to arrange, give some other time of day after the patient has not drunk for several hours. 5mls of pure colloidal silver is placed under the tongue with a glass eye-dropper. The patient holds it there for a minute and then may swallow. At least five minutes after receiving the colloidal silver, the patient has a glass of water with 2mls of Oxyrich placed in the water and stirred.

One of the three HIV/AIDS patients died shortly after commencing the treatment. He had been very close to death at the time of commencement, and it had been a risk to include him. We replaced him with another HIV/AIDS patient who commenced treatment on 9/December/06.

Before commencing the first set of pure colloidal silver + oxyrich treatment, our planning circle decided to set the daily dosage of both pure colloidal silver and oxyrich at quarter the dosage recommended by the manufacturer Australian Natural Colloids. That is, we provided to each patient 5mls of pure colloidal silver and 2mls of oxyrich daily. The reason for this decision was cost. If we could demonstrate that the product is effective at quarter the dosage recommended by the manufacturer, then further distribution in Africa would be simpler and cheaper at the smaller dosage.

The results of the first 6-months trial using quarter dosage, and commencing 22/September/05, though positive, did not diminish the viral load count over the six months. Our Inner Planning Circle therefore decided to conduct a second pure colloidal silver + oxyrich trial, which commenced 20/April/06. In this second trial, each patient each day had two treatments, one in the morning before eating or drinking, and the other in the evening. Each treatment provided to the patient 10mls of pure colloidal silver and 4mls oxyrich. And so the total product consumed by each patient daily was 20mls pure colloidal silver and 8mls oxyrich. This was four times the daily product taken by patients during the first trial, and was at the rate recommended by the manufacturer.

Blood Test Results for Trial I and Trial II

Three patients, A, B and C, commenced Trial I on 22/September/05. Following the death of patient A on 6/November/05, we selected another patient D to be included in Trial I. She commenced her treatment on 9/December/05.

Three patients, B, D and a new patient E commenced Trial II on 20/April/06, increasing the amount of product taken daily four-fold to the amount recommended by the product manufacturer.

Patient A (a 50 year-old man)

commenced treatment No I on 22/September/05
Patient A died on 6/November/05, before able to take 2-monthly blood tests

Patient B (a 43 year-old woman)

Patient C (a 57 year-old woman)

Patient D (a 53 year-old woman)

Patient E (a 37 year-old woman)

Results So Far

The 6-monthly blood samples are being taken around 20/October/06, and so should be available for publication in perhaps six more weeks. The case study records and medical examinations have not yet been forwarded for Trial I and/or Trial II and so the medical condition will be discussed in the next circular, along with the 6-months blood test results for Trial II.

Suffice to say at this stage (April/06) that all three patients were feeling continuing illness. But in the latter stages of trial II, all three patients report that they feel well. More details in the next circular.

For the moment, let us look at what the blood test results can tell us.

Patient A reported general improvement in health over the first few weeks of treatment. He went into a coma and died before we were able to take the 2-monthly blood samples for testing.

Patients B, C and D, all showed very good immunity cell count throughout the period of taking the Trial I treatment. For all three however, the viral load count remained dangerously high. This suggested that once the treatment was finished, the diseased conditions of before the treatment may likely come back. All three were therefore given a second treatment after Trial I finished. Patients B and D were included in Trial II, and patient C was gifted 6 months supply of Sutherlandia herbal tablets (to be taken without comparative survey monitoring and conditions).

All three patients B, D and E showed wonderfully healthy CD4 count at the three monthly blood tests. Patients D and E showed encouraging reduction in viral load count after three months of trial II, but patient B has not yet (at three months) shown any reduction in viral load count.

Glyconutritionals Trial in Tanzania

In Dar-es-Salaam, Tanzania, an advanced HIV/AIDS patient named Bennett commenced on 16/October/2005 a treatment involving glyconutritionals.

The treatment is by way of three types of tablets, Ambrotose AO, Plus and Catalyst, taken each day. The treatment is essentially a nutritional supplement. It has good reports of positive results with HIV/AIDS patients. Our intention was to do a complete 6-months testing trial with Bennett to provide a one-person trial to commence our own assessment of its value.

However Bennett died on 3/November/2005, from a meningitis infection.

Our coworker in Tanzania, Shadrack Kavalambi has now found another patient to undertake a comparative trial involving glyconutritionals. The male HIV patient commenced treatment on 25/July/06. Early reports indicate positive improvement in health. This trial for one person has been fully funded. We will report more on this glyconutritionals trial in future circulars.

CRN’s Funding Situation

Donations received from the public have dropped to a trickle since the beginning of 2006. Less than AUD$900 was received from the public in the first ten months of 2006.

CRN would have already been in dire financial difficulties, if it were not for an inheritance grant being received by myself, the secretary. This money was used to pay for the remainder of the cost of pure colloidal silver + oxyrich Trial I and fully paid for the cost of pure colloidal silver + oxyrich Trial II, and provided funding to buy 6-months supply of Sutherlandia herb for the next comparative trial of CRN, and paid for the cost of holding two gatherings in Kinshasa of 50 people living with HIV.

The Glyconutritionals and Pure Colloidal Silver Trial II trials are both now fully funded, but all the inheritance money has gone and the CRN fund has no more funds available for further trials.

It is vital that this Sutherlandia product be further sponsored to allow a comprehensive trial involving three advanced HIV/AIDS patients each receiving treatment over 6 months, and having proper blood tests and medical supervision. The cost for such a treatment for pure colloidal silver + oxyrich came to A$7,500 = US$5,600. A similar amount must now be raised to fund the Sutherlandia trials, and until such an amount is received or has been committed, CRN will not be able to conduct any further comparative trials.

This is a critical situation for CRN, as our public support has dropped seriously over the past year. If no more funding arrives then our projects must stop and CRN may need to be wound up. I am on a disability pension, and am able to provide enough each year only to meet the annual administrative costs of running a registered charitable organisation. The directors of CRN all work voluntarily, but we are all living in poor conditions. The funding for the trials must come from the public.

The original intention was that the comparative treatment trials would be conducted from donations received from the public. Our immediate need is to raise about A$7,500 to allow us to conduct a three person Sutherlandia trial. Do any out there believe in what we are doing sufficiently to make a major commitment and regular monthly continuing sponsorship?

Yours in love and light,
David Keane,
Secretary, Compassion Response Network

Top

Main Index --- Treatments Index --- Circulars Index